Published in Clin Vaccine Immunol on May 12, 2010
Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98
Vaccine adjuvants: putting innate immunity to work. Immunity (2010) 5.02
Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med (2011) 3.78
Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity (2013) 3.72
B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol (2012) 3.69
Rational HIV immunogen design to target specific germline B cell receptors. Science (2013) 3.55
A Blueprint for HIV Vaccine Discovery. Cell Host Microbe (2012) 3.27
Antibodies in HIV-1 vaccine development and therapy. Science (2013) 3.13
Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol (2012) 2.65
Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve. J Infect Dis (2014) 2.46
Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis (2012) 2.18
Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS (2014) 2.04
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One (2013) 1.94
JE-ADVAX vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of CD8(+) T cells and pre-exposure neutralizing antibody. J Virol (2013) 1.90
Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med (2012) 1.83
NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. Vaccine (2012) 1.77
Immunology of gut mucosal vaccines. Immunol Rev (2011) 1.59
Contributions of humoral and cellular immunity to vaccine-induced protection in humans. Virology (2011) 1.53
Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr Opin Immunol (2011) 1.51
Identification and characterization of the constituent human serum antibodies elicited by vaccination. Proc Natl Acad Sci U S A (2014) 1.50
A threshold method for immunological correlates of protection. BMC Med Res Methodol (2013) 1.41
Commentary on "Principal stratification - a goal or a tool?" by Judea Pearl. Int J Biostat (2011) 1.40
A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys. Cell Host Microbe (2015) 1.25
Development of a new hydrogen peroxide–based vaccine platform. Nat Med (2012) 1.24
A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls. PLoS One (2013) 1.23
The development of vaccines: how the past led to the future. Nat Rev Microbiol (2011) 1.19
Upregulation of IL-21 receptor on B cells and IL-21 secretion distinguishes novel 2009 H1N1 vaccine responders from nonresponders among HIV-infected persons on combination antiretroviral therapy. J Immunol (2011) 1.17
HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends Microbiol (2012) 1.13
Development of prophylactic vaccines against HIV-1. Retrovirology (2013) 1.12
Seroprevalence of measles-, mumps- and rubella-specific IgG antibodies in German children and adolescents and predictors for seronegativity. PLoS One (2012) 1.11
Moving ahead an HIV vaccine: to neutralize or not, a key HIV vaccine question. Nat Med (2011) 1.10
Design and estimation for evaluating principal surrogate markers in vaccine trials. Biometrics (2013) 1.08
Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera. Vaccine (2011) 1.07
Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines. Clin Vaccine Immunol (2014) 1.06
What Has 30 Years of HIV Vaccine Research Taught Us? Vaccines (Basel) (2013) 1.06
Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth. PLoS Pathog (2013) 1.05
Advances in structure-based vaccine design. Curr Opin Virol (2013) 1.04
Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial. J Virol (2014) 1.03
Is interferon-gamma the right marker for bacille Calmette-Guérin-induced immune protection? The missing link in our understanding of tuberculosis immunology. Clin Exp Immunol (2012) 1.03
Epidemic of mumps among vaccinated persons, The Netherlands, 2009-2012. Emerg Infect Dis (2014) 1.02
Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals. AIDS (2011) 1.02
Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future. Vaccines (Basel) (2014) 1.01
Cell-associated flagella enhance the protection conferred by mucosally-administered attenuated Salmonella Paratyphi A vaccines. PLoS Negl Trop Dis (2011) 0.99
A history of hookworm vaccine development. Hum Vaccin (2011) 0.99
Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques. J Virol (2014) 0.98
Systems biological approaches to measure and understand vaccine immunity in humans. Semin Immunol (2013) 0.98
In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nat Biotechnol (2015) 0.98
Mechanism and significance of cell type-dependent neutralization of flaviviruses. J Virol (2014) 0.98
Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. PLoS Pathog (2014) 0.97
Vaccine potential of Nipah virus-like particles. PLoS One (2011) 0.97
Development of functional and molecular correlates of vaccine-induced protection for a model intracellular pathogen, F. tularensis LVS. PLoS Pathog (2012) 0.96
Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection. PLoS Pathog (2015) 0.96
Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors. Hum Vaccin Immunother (2012) 0.96
Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes. PLoS One (2013) 0.96
Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination. Curr Opin HIV AIDS (2014) 0.95
The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response. PLoS Negl Trop Dis (2015) 0.94
Immunosignatures can predict vaccine efficacy. Proc Natl Acad Sci U S A (2013) 0.93
HIV-Host Interactions: Implications for Vaccine Design. Cell Host Microbe (2016) 0.93
Moving ahead an HIV vaccine: use both arms to beat HIV. Nat Med (2011) 0.93
Immunization with the yersiniabactin receptor, FyuA, protects against pyelonephritis in a murine model of urinary tract infection. Infect Immun (2013) 0.93
Clonal and cellular dynamics in germinal centers. Curr Opin Immunol (2014) 0.92
A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral Immunity. J Virol (2016) 0.91
Orchestration of pulmonary T cell immunity during Mycobacterium tuberculosis infection: immunity interruptus. Semin Immunol (2014) 0.91
Transcriptional profiling of vaccine-induced immune responses in humans and non-human primates. Microb Biotechnol (2011) 0.91
Directed evaluation of enterotoxigenic Escherichia coli autotransporter proteins as putative vaccine candidates. PLoS Negl Trop Dis (2011) 0.90
Associations between race, sex and immune response variations to rubella vaccination in two independent cohorts. Vaccine (2014) 0.90
Searching for the human genetic factors standing in the way of universally effective vaccines. Philos Trans R Soc Lond B Biol Sci (2015) 0.90
Measurements of immune responses for establishing correlates of vaccine protection against HIV. AIDS Res Hum Retroviruses (2011) 0.90
Optimization and qualification of a memory B-cell ELISpot for the detection of vaccine-induced memory responses in HIV vaccine trials. J Immunol Methods (2013) 0.90
Identifying gnostic predictors of the vaccine response. Curr Opin Immunol (2012) 0.89
Intrinsic differences in the initiation of B cell receptor signaling favor responses of human IgG(+) memory B cells over IgM(+) naive B cells. J Immunol (2012) 0.89
Antibody and B cell responses to Plasmodium sporozoites. Front Microbiol (2014) 0.88
Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs. Arthritis Res Ther (2013) 0.88
Efficacy of a Russian-backbone live attenuated influenza vaccine among children in Senegal: a randomised, double-blind, placebo-controlled trial. Lancet Glob Health (2016) 0.87
Role of antibodies in protection elicited by active vaccination with genetically inactivated alpha hemolysin in a mouse model of staphylococcus aureus skin and soft tissue infections. Clin Vaccine Immunol (2014) 0.87
Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients. Clin Infect Dis (2014) 0.87
Vaccinations in paediatric rheumatology: an update on current developments. Curr Rheumatol Rep (2015) 0.87
Treatment with anthelminthics during pregnancy: what gains and what risks for the mother and child? Parasitology (2011) 0.86
Lessons learned in the analysis of high-dimensional data in vaccinomics. Vaccine (2015) 0.86
Mucosal SIV Vaccines Comprising Inactivated Virus Particles and Bacterial Adjuvants Induce CD8(+) T-Regulatory Cells that Suppress SIV-Positive CD4(+) T-Cell Activation and Prevent SIV Infection in the Macaque Model. Front Immunol (2014) 0.86
A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component. J Virol (2014) 0.86
HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development. PLoS Pathog (2014) 0.85
Innate immune defects correlate with failure of antibody responses to H1N1/09 vaccine in HIV-infected patients. J Allergy Clin Immunol (2011) 0.85
Generation of cellular immune memory and B-cell immunity is impaired by natural killer cells. Nat Commun (2015) 0.85
Systems biology applied to vaccine and immunotherapy development. BMC Syst Biol (2011) 0.85
Cold chain and virus-free chloroplast-made booster vaccine to confer immunity against different poliovirus serotypes. Plant Biotechnol J (2016) 0.85
Vaccine design: emerging concepts and renewed optimism. Curr Opin Biotechnol (2013) 0.84
Induction of HIV-blocking anti-CCR5 IgA in Peyers's patches without histopathological alterations. J Virol (2014) 0.84
Seroprevalence and vaccination coverage of vaccine-preventable diseases in perinatally HIV-1-infected patients. Hum Vaccin Immunother (2014) 0.84
Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: An integrated analysis. Hum Vaccin Immunother (2015) 0.84
Broad antibody and T cell reactivity induced by a pneumococcal whole-cell vaccine. Vaccine (2012) 0.84
Immune-complex mimics as a molecular platform for adjuvant-free vaccine delivery. PLoS One (2013) 0.84
An Overview of Challenges Limiting the Design of Protective Mucosal Vaccines for Finfish. Front Immunol (2015) 0.83
Computational prediction of broadly neutralizing HIV-1 antibody epitopes from neutralization activity data. PLoS One (2013) 0.83
Vaccination of healthcare workers: A review. Hum Vaccin Immunother (2015) 0.83
Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses. J Allergy Clin Immunol (2012) 0.83
Native-like Env trimers as a platform for HIV-1 vaccine design. Immunol Rev (2017) 0.83
Serology in the 21st century: the molecular-level analysis of the serum antibody repertoire. Curr Opin Immunol (2015) 0.82
Host-Brucella interactions and the Brucella genome as tools for subunit antigen discovery and immunization against brucellosis. Front Cell Infect Microbiol (2013) 0.82
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med (2005) 17.06
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med (2007) 15.40
Pathogenesis of dengue: challenges to molecular biology. Science (1988) 14.73
IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol (2007) 10.71
Research on dengue during World War II. Am J Trop Med Hyg (1952) 8.76
Duration of antiviral immunity after smallpox vaccination. Nat Med (2003) 7.39
Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis (2008) 5.69
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet (2009) 5.68
T cell responses are better correlates of vaccine protection in the elderly. J Immunol (2006) 4.38
Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med (2006) 4.23
Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A (1995) 4.15
Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol (1995) 4.14
The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis (1983) 4.05
Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr Res (1973) 3.89
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology (2004) 3.85
Measles antibody: reevaluation of protective titers. J Infect Dis (1990) 3.77
The prevention of hepatitis B with vaccine. Report of the centers for disease control multi-center efficacy trial among homosexual men. Ann Intern Med (1982) 3.69
Cell-mediated protection in influenza infection. Emerg Infect Dis (2006) 3.62
Distribution of poliovirus antibody in serum, nasopharynx and alimentary tract following segmental immunization of lower alimentary tract with poliovaccine. J Immunol (1969) 3.49
Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med (1977) 3.32
On immunity against infections and vaccines: credo 2004. Scand J Immunol (2004) 3.29
Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines. Vaccine (1998) 3.22
Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest (2009) 3.16
Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog (2010) 3.16
Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis (1999) 3.15
Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine (1998) 3.10
A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine (1998) 3.07
The immune response to pneumococcal proteins during experimental human carriage. J Exp Med (2002) 3.03
In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine (2001) 3.03
Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis (2000) 2.90
Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine (2003) 2.87
Meningococcal surrogates of protection--serum bactericidal antibody activity. Vaccine (2005) 2.81
Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b: a field trial in Finland. J Infect Dis (1977) 2.79
Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol (2001) 2.78
A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology (1982) 2.74
Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immun (2001) 2.67
Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol (1986) 2.67
Antibody response in serum and nasopharynx after naturally acquired and vaccine-induced infection with rubella virus. N Engl J Med (1971) 2.62
Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat Med (2010) 2.61
Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst (2003) 2.58
Immunity and immunological memory following smallpox vaccination. Immunol Rev (2006) 2.57
THE PROPHYLACTIC DOSE OF HOMOLOGOUS TETANUS ANTITOXIN. N Engl J Med (1964) 2.55
CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system. J Virol (2006) 2.44
Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J Infect Dis (2008) 2.37
Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J (2001) 2.31
Varicella in children with cancer: Seventy-seven cases. Pediatrics (1975) 2.29
Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine (2004) 2.28
Systematic and intestinal antibody-secreting cell responses and correlates of protective immunity to human rotavirus in a gnotobiotic pig model of disease. J Virol (1996) 2.25
Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis (2008) 2.25
Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis (2009) 2.13
The role of secondary vaccine failures in measles outbreaks. Am J Public Health (1989) 2.10
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign. Commun Dis Public Health (2003) 2.08
Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. J Hepatol (1994) 2.08
Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies. J Infect Dis (2010) 2.08
Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine (2007) 2.07
Viremia, virus excretion, and antibody responses after challenge in volunteers with low levels of antibody to rubella virus. J Infect Dis (1983) 2.07
Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis (2000) 2.04
What level of hepatitis B antibody is protective? J Infect Dis (1999) 2.02
Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol (2008) 1.96
Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Methods (1981) 1.96
Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J Infect Dis (1989) 1.89
Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. A family study during a type 1 poliomyelitis epidemic. Am J Hyg (1962) 1.82
Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J Virol (2008) 1.77
Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis (2003) 1.76
Immunity and correlates of protection for rotavirus vaccines. Vaccine (2006) 1.73
Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Vaccine (2006) 1.73
Specific prophylaxis of tetanus. J Am Med Assoc (1959) 1.73
Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine (1996) 1.72
The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol (2009) 1.71
Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine (2009) 1.69
Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine (2005) 1.67
Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. J Infect Dis (1991) 1.66
A prospective study of serum antibody and protection against smallpox. Am J Trop Med Hyg (1972) 1.62
Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function. J Virol (2006) 1.62
Early activation of natural killer and B cells in response to primary dengue virus infection in A/J mice. Virology (2004) 1.61
Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J Infect Dis (2005) 1.61
Increased mumps incidence in the Netherlands: review on the possible role of vaccine strain and genotype. Euro Surveill (2008) 1.58
Measles and measles immunity in children infected with human immunodeficiency virus. JAMA (1989) 1.56
Six years' follow-up after hepatitis A vaccination. N Engl J Med (1998) 1.55
FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. Vaccine (2008) 1.55
The role of serum antibodies in the protection against rotavirus disease: an overview. Clin Infect Dis (2002) 1.53
The protective role of antibody responses during Mycobacterium tuberculosis infection. Clin Exp Immunol (2009) 1.48
Rubella immunity. Defining the level of protective antibody. Am J Clin Pathol (1996) 1.46
Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks? Clin Infect Dis (2008) 1.42
Immunological correlates of protection from HIV infection and disease. Nat Immunol (2006) 1.40
Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses. Epidemiol Infect (1989) 1.40
The serological assessment of a tetanus toxoid field trial. Bull World Health Organ (1971) 1.40
Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis (2003) 1.40
Lymphocyte responses to varicella zoster virus in the elderly. J Clin Immunol (1987) 1.37
Correlates of immune protection and the development of a human immunodeficiency virus vaccine. Immunity (2007) 1.36
Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol (1973) 1.35
Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits. Infect Immun (2006) 1.35
Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J Infect Dis (1990) 1.34
Correlates of protective immunity in poxvirus infection: where does antibody stand? Immunol Cell Biol (2007) 1.33
In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. Infect Immun (2007) 1.33
Active immunity against rotavirus infection in mice is correlated with viral replication and titers of serum rotavirus IgA following vaccination. Virology (1994) 1.33
Antibody responses in serum and nasal secretions of children immunized with inactivated and attenuated measles-virus vaccines. N Engl J Med (1969) 1.32
The development of vaccines: how the past led to the future. Nat Rev Microbiol (2011) 1.19